These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 33803255)

  • 21. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases.
    Lin L; Zhang J
    BMC Immunol; 2017 Jan; 18(1):2. PubMed ID: 28061847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the gut microbiota in the treatment of inflammatory bowel diseases.
    Aggeletopoulou I; Konstantakis C; Assimakopoulos SF; Triantos C
    Microb Pathog; 2019 Dec; 137():103774. PubMed ID: 31586663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biome engineering-2020.
    Brüssow H
    Microb Biotechnol; 2016 Sep; 9(5):553-63. PubMed ID: 27471167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current understanding of the role of gut dysbiosis in type 1 diabetes.
    Abdellatif AM; Sarvetnick NE
    J Diabetes; 2019 Aug; 11(8):632-644. PubMed ID: 30864231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut microbiota and inflammatory bowel disease: so far so gut!
    Holleran G; Lopetuso LR; Ianiro G; Pecere S; Pizzoferrato M; Petito V; Graziani C; McNAMARA D; Gasbarrini A; Scaldaferri F
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):373-384. PubMed ID: 28293937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Gut Microbiota in Type 2 Diabetes Mellitus and Its Complications: Novel Insights and Potential Intervention Strategies.
    Woldeamlak B; Yirdaw K; Biadgo B
    Korean J Gastroenterol; 2019 Dec; 74(6):314-320. PubMed ID: 31870137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbiota derived factors as drivers of type 1 diabetes.
    Tillett BJ; Hamilton-Williams EE
    Prog Mol Biol Transl Sci; 2020; 171():215-235. PubMed ID: 32475523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease.
    Sun MF; Shen YQ
    Ageing Res Rev; 2018 Aug; 45():53-61. PubMed ID: 29705121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut microbiome and type 2 diabetes: where we are and where to go?
    Sharma S; Tripathi P
    J Nutr Biochem; 2019 Jan; 63():101-108. PubMed ID: 30366260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of gut microbiota by bioactive compounds for prevention and management of type 2 diabetes.
    Sharma BR; Jaiswal S; Ravindra PV
    Biomed Pharmacother; 2022 Aug; 152():113148. PubMed ID: 35665671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of diet and intestinal microbiota in the development of metabolic syndrome.
    Santos-Marcos JA; Perez-Jimenez F; Camargo A
    J Nutr Biochem; 2019 Aug; 70():1-27. PubMed ID: 31082615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The gut microbiota, a new cardiovascular risk factor?].
    Chong-Nguyen C; Duboc H; Sokol H
    Presse Med; 2017; 46(7-8 Pt 1):708-713. PubMed ID: 28756077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism.
    Amabebe E; Robert FO; Agbalalah T; Orubu ESF
    Br J Nutr; 2020 May; 123(10):1127-1137. PubMed ID: 32008579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis and faecal microbiome transplantation: are you going to eat that?
    Wing AC; Kremenchutzky M
    Benef Microbes; 2019 Feb; 10(1):27-32. PubMed ID: 30525949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut microbiome in chronic kidney disease: challenges and opportunities.
    Nallu A; Sharma S; Ramezani A; Muralidharan J; Raj D
    Transl Res; 2017 Jan; 179():24-37. PubMed ID: 27187743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress with treating the microbial dysbiosis associated with irritable bowel syndrome.
    Pearson JS; Whorwell PJ
    Curr Opin Gastroenterol; 2017 Jan; 33(1):21-25. PubMed ID: 28134688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possibilities of therapeutic manipulation of the gut microbiota.
    Drastich P; Bajer L; Kverka M
    Vnitr Lek; 2018; 64(6):665-671. PubMed ID: 30223665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.